Saturday, 31 October 2020

PRO/EDR> Gonococcal disease: rapid point-of-care testing, targeted therapy

Antimicrobial resistance -- Worldwide/Unknown
Background: Widespread ceftriaxone antimicrobial resistance (AMR) threatens _Neisseria gonorrhoeae_ (NG) treatment, with few alternatives available. AMR point-of-care tests (AMR POCT) may enable alternative treatments, including abandoned regimens, sparing ceftriaxone use. We assessed cost-effectiveness of 5 hypothetical AMR POCT strategies: A-C included a 2nd antibiotic alongside ceftriaxone; D and E consisted of a single antibiotic alternative, compared with standard care (SC: ceftriaxone

Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7904955&promed&0

No comments:

Post a Comment